Variation in Anticoagulant Recommendations by the Guidelines and Decision Tools among Patients with Atrial Fibrillation
- PMID: 27417752
- PMCID: PMC4934528
- DOI: 10.3390/healthcare3010130
Variation in Anticoagulant Recommendations by the Guidelines and Decision Tools among Patients with Atrial Fibrillation
Abstract
Published atrial fibrillation (AF) guidelines and decision tools offer oral anticoagulant (OAC) recommendations; however, they consider stroke and bleeding risk differently. The aims of our study are: (i) to compare the variation in OAC recommendations by the 2012 American College of Chest Physicians guidelines, the 2012 European Society of Cardiology (ESC) guidelines, the 2014 American Heart Association (AHA) guidelines and two published decision tools by Casciano and LaHaye; (ii) to compare the concordance with actual OAC use in the overall study population and the population stratified by stroke/bleed risk. A cross-sectional study using the 2001-2013 Lifelink claims data was used to contrast the treatment recommendations by these decision aids. CHA₂DS₂-VASc and HAS-BLED algorithms were used to stratify 15,129 AF patients into nine stroke/bleed risk groups to study the variation in treatment recommendations and concordance with actual OAC use/non-use. The AHA guidelines which were set to recommend OAC when CHA₂DS₂-VASc = 1 recommended OAC most often (86.30%) and the LaHaye tool recommended OAC the least often (14.91%). OAC treatment recommendations varied considerably when stroke risk was moderate or high (CHA₂DS₂-VASc > 0). Actual OAC use/non-use was highly discordant (>40%) with all of the guidelines or decision tools reflecting substantial opportunities to improve AF OAC decisions.
Keywords: atrial fibrillation; decision tools; guidelines; oral anticoagulants; overuse; recommendations; underuse; warfarin.
Figures

Similar articles
-
Net Clinical Benefits of Guidelines and Decision Tool Recommendations for Oral Anticoagulant Use among Patients with Atrial Fibrillation.J Stroke Cerebrovasc Dis. 2015 Dec;24(12):2845-53. doi: 10.1016/j.jstrokecerebrovasdis.2015.08.019. Epub 2015 Oct 21. J Stroke Cerebrovasc Dis. 2015. PMID: 26482369 Free PMC article.
-
Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline.J Am Heart Assoc. 2018 Jan 4;7(1):e007881. doi: 10.1161/JAHA.117.007881. J Am Heart Assoc. 2018. PMID: 29301756 Free PMC article.
-
Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS2 to the CHA2DS2-VASc Score for Thromboembolic Risk Assessment: Analysis From the National Cardiovascular Data Registry's Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry.Circ Cardiovasc Qual Outcomes. 2017 May;10(5):e003476. doi: 10.1161/CIRCOUTCOMES.116.003476. Circ Cardiovasc Qual Outcomes. 2017. PMID: 28506981
-
The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society.Korean Circ J. 2015 Jan;45(1):9-19. doi: 10.4070/kcj.2015.45.1.9. Epub 2015 Jan 26. Korean Circ J. 2015. PMID: 25653698 Free PMC article. Review.
-
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).Europace. 2017 Nov 1;19(11):1757-1758. doi: 10.1093/europace/eux240. Europace. 2017. PMID: 29096024 Review.
Cited by
-
Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.J Manag Care Spec Pharm. 2017 Sep;23(9):958-967. doi: 10.18553/jmcp.2017.23.9.958. J Manag Care Spec Pharm. 2017. PMID: 28854077 Free PMC article.
-
A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras.Drugs Aging. 2016 Jun;33(6):427-36. doi: 10.1007/s40266-016-0369-y. Drugs Aging. 2016. PMID: 27154397
-
Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.J Manag Care Spec Pharm. 2016 Nov;22(11):1319-1329. doi: 10.18553/jmcp.2016.22.11.1319. J Manag Care Spec Pharm. 2016. PMID: 27783556 Free PMC article.
-
Net Clinical Benefits of Guidelines and Decision Tool Recommendations for Oral Anticoagulant Use among Patients with Atrial Fibrillation.J Stroke Cerebrovasc Dis. 2015 Dec;24(12):2845-53. doi: 10.1016/j.jstrokecerebrovasdis.2015.08.019. Epub 2015 Oct 21. J Stroke Cerebrovasc Dis. 2015. PMID: 26482369 Free PMC article.
-
Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry.Med Sci Monit. 2019 Jun 24;25:4691-4698. doi: 10.12659/MSM.917131. Med Sci Monit. 2019. PMID: 31232394 Free PMC article.
References
-
- Singer D.E., Albers G.W., Dalen J.E., Fang M.C., Go A.S., Halperin J.L., Lip G.Y., Manning W.J. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008;133:546S–592S. doi: 10.1378/chest.08-0678. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources